Loading
Metabolism, Diabetes, and Cancer · Journal article
Frontiers in Immunology · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical mechanistic study demonstrating that carnosic acid combined with 5-fluorouracil suppresses proliferation, migration, invasion, and EMT in 5-FU-resistant gastric cancer cells and mouse models, while enhancing CD8+ T cell cytotoxicity, apparently via inhibition of the CXCL12/CXCR7 axis. The work raises a hypothesis about CA's potential in resistant gastric cancer but provides no human efficacy data, quantified effect sizes, or safety metrics to support clinical translation.
Preclinical mechanistic study using cell lines and mouse xenograft models. 5-FU-sensitive and 5-FU-resistant gastric cancer cell lines; MFC and MFC-R mouse gastric cancer models. Intervention: Carnosic acid (CA) combined with 5-fluorouracil (5-FU). Compared with: 5-FU alone; CXCR7 overexpression reversal experiments.
CA plus 5-FU suppressed proliferation, migration, invasion, and EMT while promoting apoptosis in resistant GC cells CXCR7 overexpression partially reversed CA's sensitizing effects, supporting mechanistic specificity Combined treatment enhanced CD8+ T cell proliferation and expression of cytotoxic mediators (IFN-γ and Granzyme B)
No detailed safety or toxicology data provided beyond 'no obvious systemic toxicity' No obvious systemic toxicity was observed in safety models
These findings warrant further preclinical validation and, if confirmed, could justify early-phase clinical trials to test whether carnosic acid can overcome 5-FU resistance in human gastric cancer. However, no human efficacy or safety data are yet available to guide clinical practice.
Preclinical study using cell lines and mouse models with mechanistic findings; no human trials, no clinical efficacy data, and no quantified effect sizes reported.
As stated by the source record.
These findings warrant further preclinical validation and, if confirmed, could justify early-phase clinical trials to test whether carnosic acid can overcome 5-FU resistance in human gastric cancer. However, no human efficacy or safety data are yet available to guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background Key features of gastric cancer (GC) include its aggressive nature, high metastatic capability, and a tendency for relapse. While 5-fluorouracil (5-FU) remains a cornerstone of GC treatment, its efficacy is substantially undermined by the emergence of acquired drug resistance. Carnosic acid (CA) has antitumor and immunomodulatory potential, but its role in 5-FU-resistant GC remains unclear. This study investigated whether CA enhances 5-FU sensitivity and CD8 + T cell-mediated antitumor immunity by regulating the CXCL12/CXCR7 axis. Methods The effects of CA combined with 5-FU on cell viability, proliferation, apoptosis, migration, invasion, and EMT-related features were evaluated using 5-FU-sensitive and 5-FU-resistant GC cell models and MFC/MFC-R mouse GC models. CXCR7 overexpression, co-immunoprecipitation, immunofluorescence, and Western blotting were performed to examine CXCL12/CXCR7-axis regulation. GC cell/CD8 + T cell co-culture, subcutaneous tumor, lung metastasis, anti-PD-L1 combination therapy, and safety models were further used for validation. Results 5-FU-resistant GC cells showed reduced drug sensitivity and enhanced malignant phenotypes. CA plus 5-FU suppressed proliferation, migration, invasion, and EMT, while promoting apoptosis. Mechanistically, CA restored 5-FU sensitivity by inhibiting aberrant CXCL12/CXCR7-axis activation, whereas CXCR7 overexpression partially reversed these effects. The combined treatment also enhanced CD8 + T cell proliferation, cytotoxicity, and IFN-γ and Granzyme B expression, reduced immunosuppression-associated molecules, inhibited tumor growth and lung metastasis, potentiated anti-PD-L1 efficacy, and caused no obvious systemic toxicity. Conclusion CA enhances 5-FU sensitivity, suppresses EMT and metastasis-associated phenotypes, and improves CD8 + T cell-mediated antitumor immunity in resistant GC by targeting the CXCL12/CXCR7 axis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.